Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

Phase 3

Completed

Conditions: Colitis, Ulcerative

Interventions: Drug: Vedolizumab
Drug: Adalimumab
Drug: Vedolizumab placebo
Drug: Adalimumab placebo

First Posted Date: 2015-07-14

Last Posted Date: 2020-01-28

Lead Sponsor: Takeda

Target Recruit Count: 771

Registration Number: NCT02497469

Locations: 🇺🇸
Chevy Chase Clinical Research, Chevy Chase, Maryland, United States
🇺🇸
Texas Digestive Disease Consultants - Dallas, Dallas, Texas, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 326 locations

A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935

Phase 1

Completed

Conditions: Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents

Interventions: Drug: TAK-935
Drug: [18F]MNI-792 (tracer)

First Posted Date: 2015-07-14

Last Posted Date: 2017-04-11

Lead Sponsor: Takeda

Target Recruit Count: 11

Registration Number: NCT02497235

Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension

Phase 3

Completed

Conditions: Essential Hypertension

Interventions: Drug: Azilsartan medoxomil
Drug: Valsartan
Drug: Azilsartan medoxomil Placebo
Drug: Valsartan Placebo

First Posted Date: 2015-06-24

Last Posted Date: 2019-03-05

Lead Sponsor: Takeda

Target Recruit Count: 612

Registration Number: NCT02480764

Locations: 🇨🇳
Beijing Chao Yang Hospital, Beijing, Beijing, China
🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳
Beijing Anzhen Hospital, Beijing, Beijing, China

and more 27 locations

A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-648 Tablet
Drug: TAK-648 Oral Solution

First Posted Date: 2015-06-24

Last Posted Date: 2016-08-31

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT02480439

A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: TAK-063 20 mg

First Posted Date: 2015-06-22

Last Posted Date: 2017-09-29

Lead Sponsor: Takeda

Target Recruit Count: 164

Registration Number: NCT02477020

Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine

Phase 2

Completed

Conditions: Norovirus
Healthy Participants

Interventions: Biological: NoV GI.1/GII.4 Bivalent VLP Vaccine

First Posted Date: 2015-06-18

Last Posted Date: 2018-02-22

Lead Sponsor: Takeda

Target Recruit Count: 50

Registration Number: NCT02475278

Locations: 🇺🇸
Benchmark Research Austin, Austin, Texas, United States

Epidemiological Study in Thai Participants With Hypertension

Completed

Conditions: Hypertension

Interventions: Other: No Intervention

First Posted Date: 2015-06-10

Last Posted Date: 2015-11-13

Lead Sponsor: Takeda

Target Recruit Count: 2071

Registration Number: NCT02467855

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

Phase 2

Active, not recruiting

Conditions: Myeloid Leukemia, Chronic, Chronic Phase

Interventions: Drug: Ponatinib

First Posted Date: 2015-06-10

Last Posted Date: 2025-01-08

Lead Sponsor: Takeda

Target Recruit Count: 283

Registration Number: NCT02467270

Locations: 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇨🇦
Saskatchewan Cancer Agency, Regina, Saskatchewan, Canada
🇬🇧
Imperial College Healthcare NHS Trust, London, England, United Kingdom

and more 83 locations

Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-915 suspension
Drug: Placebo
Drug: TAK-915 tablet
Drug: Midazolam

First Posted Date: 2015-06-03

Last Posted Date: 2019-02-15

Lead Sponsor: Takeda

Target Recruit Count: 88

Registration Number: NCT02461160

Calcichew D3 Preference Study in Participants Eligible for Calcium and Vitamin D Supplementation.

Phase 4

Completed

Conditions: Calcium and Vitamin D Deficiencies

Interventions: Drug: Calcichew D3
Drug: Kalcipos-D
Drug: Adcal-D3

First Posted Date: 2015-05-29

Last Posted Date: 2016-10-25

Lead Sponsor: Takeda

Target Recruit Count: 276

Registration Number: NCT02457247

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy